Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 12/20 | 0.46 |
| ▸ | CTSK | P43235 | 6/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30278382 | 0.83 | REN (0.44) | RENCTSKCTSS | |
| SCHEMBL23005013 | 0.83 | REN (0.45) | RENCTSKCTSS | |
| SCHEMBL8140311 | 0.74 | REN (0.60) | RENCTSKCTSS | |
| SCHEMBL3827253 | 0.74 | REN (0.58) | RENCTSKCTSS | |
| SCHEMBL3823930 | 0.73 | REN (0.56) | RENCTSKCTSS | |
| SCHEMBL12203697 | 0.71 | CTSK (0.59) | RENCTSKCTSSCACNA1B | |
| SCHEMBL23005010 | 0.71 | CTSL (0.45) | CTSKCTSS | |
| SCHEMBL25288550 | 0.71 | CTSK (0.59) | RENCTSKCTSSCACNA1B | |
| SCHEMBL25288551 | 0.71 | CTSK (0.59) | RENCTSKCTSSCACNA1B | |
| SCHEMBL8141216 | 0.71 | REN (0.56) | RENCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230102879-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-03-30 | — | — | US | disclosed |
| US-11261201-B2 | TRNA synthetase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-03-01 | — | — | US | disclosed |
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | REN 2951/4885CTSK 2871/4885CTSS 428/4885 |
| US-20230102879-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | REN 2951/4885CTSK 2871/4885CTSS 428/4885 |
| US-11261201-B2 | TRNA synthetase inhibitors | TRMT1, AARS1, GARS1 | REN 2951/4885CTSK 2871/4885CTSS 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.